According to a multi-center clinical trial led by researchers at the Stanford University School of Medicine, a new type of immunotherapy seems to be safe for patients with blood cancer called non-Hodgkin’s lymphoma.
The therapy combines experimental antibodies developed by researchers at Stanford University and commercially available anti-cancer antibodies to rituximab. It referred Hu5F9-G4 experimental protein antibody blockade of CD47 , of CD47 suppressed immune attack against cancer cells. The combination of two antibodies is used to treat people with two types of ne-Hodžkina limfoma: diffuse large B- cell lymphoma and follicular lymphoma.
2010. gadā Stenfordas cilmes šūnu bioloģijas un reģeneratīvās medicīnas institūta direktora, MD Irvinga Veismana vadītie pētnieki parādīja, ka gandrīz visas vēža šūnas ir pārklātas ar olbaltumvielu, ko sauc par CD47, kas var atskaņot signālu "neēd mani". makrofāgiem.
Weissman and colleagues later developed an antibody called Hu5F9-G4 that blocks the CD47 protein and encourages macrophages to engulf cancer cells. Rituximab is an antibody that has been shown to amplify the positive ” eat me ” signal. The combination of rituximab and Hu5F-G4 has previously been shown to be effective against human cancer in animal models, but this is the first published result of clinical trials of the therapy in humans.
No 22 pacientiem, kas piedalījās pētījumā, 11 pacientiem bija ievērojami samazināts klīniskais vēzis, un 8 pacientiem bija novērstas visas vēža pazīmes. Pārējie trīs pētījuma pacienti nereaģēja uz ārstēšanu un nomira slimības progresēšanas dēļ. Pētnieki novēroja, ka dalībniekiem bija tikai nelielas blakusparādības.
Dr. Saul A. Rosenberg , a lymphoma professor , said that such a potential new imūnterapiju is very exciting. This is the first time that an antibody that can activate macrophages to fight cancer is used, and it seems to be safe for use in humans.
https://medicalxpress.com/news/2018-10-anti-cd47-cancer-therapy-safe-small.html
